NewsMeter
Moderna's (NASDAQ: MRNA) $61.2 billion market cap is more than twice BioNTech's (NASDAQ: BNTX) $26 billion: a 2x floor implies $52 billion, leaving Moderna $9.2 billion above it.
Both companies' financial results have deteriorated since pandemic-era peaks, and both have lagged broader equities over the past five years.
The spread prices pipeline execution, specifically Moderna's recent late-stage wins against BioNTech's yet-to-be-validated candidates.
| | Moderna (MRNA) | BioNTech (BNTX) | |---|---|---| | Market cap (reported) | $61.2 billion | $26 billion | | Key oncology late-stage win | Ph3: intismeran autogene (melanoma, with Merck) | None yet | | Recent regulatory win | mFLUSIVA (U.S., influenza) | None | | Notable setback | COVID franchise no longer growth driver | Ph2 autogene cevumeran halted | Moderna's late-stage scorecard Investor concern had centered on whether Moderna could generate meaningful revenue beyond the COVID-19 market.
Keep reading